OLIG2 inhibitor shows promise in treatment-resistant brain tumors in preclinical models. Feb. 11, 2025. By Tamra Sami. Researchers from the QIMR Berghofer Medical Research Institute in Queensland, ...

“Our study demonstrated that the OLIG2 protein is a critical driver of the complex early stages of medulloblastoma tumor formation, making it a highly promising treatment target,” Dirks says. “We ...

OLIG2 activates dormant cancer stem cells, driving medulloblastoma formation and relapse. Blocking OLIG2 with CT-179 prevented tumors from forming and increased survival rates in preclinical models.

"We showed that inhibiting the OLIG2 protein with the CT-179 drug prevented cancer stem cells from changing to a proliferative state, effectively blocking the growth and recurrence of tumors.

They found that early in tumor development and after conventional treatments, a protein called OLIG2 would activate 'sleeping' stem cells, causing them to divide and grow into a tumor.

1 Department of Histology and Neuroanatomy, Tokyo Medical University, Tokyo, Japan; 2 Department of Legal Medicine, Osaka University, Suita, Japan; Astrocytes are key components of the neurovascular ...

Reviewer #2 (Public Review): Summary: Here the authors show a novel direct neuronal reprogramming model using a very pure culture system of oligodendrocyte progenitor cells and demonstrate hallmarks ...

Yokoo H, Nobusawa S, Takebayashi H, et al. Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas[J]. The American journal of pathology, ...

Olig2 encodes a basic helix–loop–helix (bHLH) transcription factor that is required for the specification of oligodendrocyte precursor cells (OPCs) and differentiation of oligodendrocytes (18–21).